Clinical Trial

Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy

Study acronym: G360-IIT
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This clinical trial plans to assess to what extent the on-treatment circulating tumor DNA (ctDNA) can predict the subset of patients with NSCLC who will respond to immunotherapy treatment only and which patients will need both immunotherapy and chemotherapy modalities for their treatment regimen.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2023-01-27; most recent amendment 2026-02-17.
Status change: Not Yet Recruiting → Recruiting 2023-10-19
Trial Details
NCT Number NCT05715229
Lead Sponsor Hackensack Meridian Health
Collaborators: MedSIR
Conditions Carcinoma, Non-Small-Cell Lung
Enrollment 108 participants
Start Date 2023-09-29
Primary Completion 2027-04-28 (estimated)
Study Completion 2027-04-28 (estimated)
Updated on ClinicalTrials.gov 2026-02-18